Long-Term Safety and Tolerability of Nizubaglustat in Participants With Rare Lysosomal Disorders | MicrobiomeTrials← Back to trialsNCT07885917
Long-Term Safety and Tolerability of Nizubaglustat in Participants With Rare Lysosomal Disorders
RecruitingPHASE2, PHASE3INTERVENTIONAL
Trial Details
Start: 2026-12-10Est. Completion: 2030-04-01
Enrollment target: 218 participants Other microbiome trials you might be interested in
Niemann-Pick Disease, Type C
This study will evaluate clinical and laboratory tests that might be useful in determining if an investigational drug ca…
Bethesda, United States
GM2 GangliosidosisNiemann-Pick Type C Disease
This open-label study aims to gather long-term safety, tolerability, PK, biomarker, and clinical efficacy data relating …
Água Verde, BrazilEst. completion Jun 30, 2027